رجوع
نطاق اليوم
KWD 27.66
KWD 28.39
نطاق 52 أسبوعًا
KWD 8.73
KWD 30.33
حجم التداول
4,814,209
متوسط 50 يوم / 200 يوم
KWD 25.80
/
KWD 18.18
الإغلاق السابق
KWD 27.70
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (626 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -116.2 | 0.4 |
| P/B | 4.3 | 2.9 |
| ROE % | -3.2 | 3.7 |
| Net Margin % | -592.0 | 3.8 |
| Rev Growth 5Y % | 5.1 | 10.0 |
| D/E | 0.0 | 0.2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 13, 2026 |
QVT Financial LP
|
sell | 375,784 | KWD 26.490 | KWD 9,956,768 |
| Feb 12, 2026 |
QVT Financial LP
|
sell | 425,000 | KWD 26.720 | KWD 11,367,000 |
| Feb 11, 2026 |
QVT Financial LP
|
sell | 425,000 | KWD 26.670 | KWD 11,334,750 |
| Dec 17, 2025 |
QVT Financial LP
|
sell | 777,332 | KWD 23.050 | KWD 17,935,595 |
| Dec 16, 2025 |
QVT Financial LP
|
sell | 917,282 | KWD 22.930 | KWD 21,129,619 |
| Nov 20, 2025 |
Venker Eric
President & Immunovant CEO
|
other | 7,051 | KWD 20.270 | KWD 142,924 |
| Nov 19, 2025 |
QVT Financial LP
|
sell | 1,300,000 | KWD 20.250 | KWD 26,304,500 |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
grant | 789 | — | — |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
other | 158 | KWD 17.740 | KWD 2,803 |
| Sep 28, 2025 |
Pulik Richard
CFO
|
other | 2,341 | KWD 15.170 | KWD 35,513 |
| Jul 28, 2025 |
Pulik Richard
CFO
|
other | 1,919 | KWD 11.350 | KWD 21,781 |
| Jul 17, 2025 |
Epperly Melissa B,
|
grant | 1,609 | — | — |
| Jun 25, 2025 |
Gold Daniel Allen
|
other | 36,756,758 | — | — |
| Jun 25, 2025 |
MANCHESTER KEITH S
|
other | 17,389,525 | — | — |
| Jun 25, 2025 |
QVT Financial LP
|
other | 36,756,758 | — | — |
| Jun 20, 2025 |
Pulik Richard
CFO
|
other | 1,503 | KWD 11.450 | KWD 17,209 |
| May 20, 2025 |
Gline Matthew
CEO
|
other | 10,945 | KWD 11.040 | KWD 120,833 |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
grant | 1,379 | — | — |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
other | 276 | KWD 10.150 | KWD 2,801 |
| Apr 17, 2025 |
Epperly Melissa B,
|
grant | 1,847 | — | — |
النقاط الرئيسية
Revenue grew 5.12% annually over 5 years — modest growth
Earnings declined -103.95% over the past year
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -844.05M
PEG of 0.41 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 16.31%
النمو
Revenue Growth (5Y)
5.12%
Revenue (1Y)-11.19%
Earnings (1Y)-103.95%
FCF Growth (3Y)N/A
الجودة
Return on Equity
-3.23%
ROIC-15.72%
Net Margin-591.96%
Op. Margin-3453.32%
الأمان
Debt / Equity
0.02
Current Ratio33.47
Interest Coverage0.00
التقييم
P/E Ratio
-116.23
P/B Ratio4.26
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -11.19% | Revenue Growth (3Y) | -31.14% |
| Earnings Growth (1Y) | -103.95% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 5.12% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 29.05M | Net Income (TTM) | -171.98M |
| ROE | -3.23% | ROA | -3.16% |
| Gross Margin | 96.86% | Operating Margin | -3453.32% |
| Net Margin | -591.96% | Free Cash Flow (TTM) | -844.05M |
| ROIC | -15.72% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.02 | Current Ratio | 33.47 |
| Interest Coverage | 0.00 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -116.23 | P/B Ratio | 4.26 |
| P/S Ratio | 688.04 | PEG Ratio | 0.41 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 19.99B | Enterprise Value | 17.37B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 29.05M | 32.71M | 61.28M | 55.29M | 23.80M |
| Net Income | -171.98M | 4.35B | -1.01B | -845.26M | -809.23M |
| EPS (Diluted) | -0.24 | 5.23 | -1.42 | -1.26 | -1.18 |
| Gross Profit | 28.14M | 31.11M | 48.15M | 46.32M | 21.74M |
| Operating Income | -1.00B | 4.50B | -1.18B | -1.35B | -1.07B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B |
| Total Liabilities | 249.74M | 773.95M | 782.02M | 523.70M | 527.69M |
| Shareholders' Equity | 4.69B | 5.97B | 1.16B | 1.66B | 1.90B |
| Total Debt | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M |
| Cash & Equivalents | 2.72B | 6.54B | 1.68B | 2.06B | 2.13B |
| Current Assets | 5.00B | 6.73B | 1.80B | 2.15B | 2.19B |
| Current Liabilities | 149.41M | 266.76M | 272.45M | 184.37M | 218.96M |